Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with ...

Pfizer (PFE) announced that it has selected its preferred once-daily modified-release formulation of danuglipron, its oral GLP-1 receptor agonist, for further development as a weight loss pill based on encouraging results from an ongoing study. It evaluated several formulations of danuglipron and said that one showed “the most favorable profile.” Pfizer, however, did not announce any detailed clinical data from the study.In the second half of the year, Pfizer will conduct dose optimization studies on multip ...

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice-daily version of the drug late last year.The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lillyand Novo Nordisk that will offer patients a more convenient alternative to injections.Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk’s ...

Key TakeawaysPfizer shares rose as the company said it would be moving forward with studies of a once-a-day oral weight-loss pill after testing its modified release formulation.The pill has the same GLP-1 receptor agonists used in the injectable obesity treatments from Novo Nordisk and Eli Lilly.Pfizer reported the drug was successful when given twice a day, but caused adverse side effects. Shares of Pfizer (PFE) advanced as the drug maker announced that it was moving forward with research into a potential ...

On Thursday, Pfizer announced plans to advance its weight-loss pill after "encouraging" results from an early-stage study.  The pharmaceutical giant is trying to tap into the highly lucrative market for obesity drugs currently dominated by the likes of Eli Lilly and Novo Nordisk. HIMS & HERS ROLLS OUT WEIGHT-LOSS SHOTS MUCH CHEAPER THAN OZEMPIC, WEGOVY Pfizer said it has a "robust pipeline" of three clinical and several other pre-clinical candidates but that danuglipron, a once-a-day oral treatment, was "th ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesWe believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly. There is more to the compariso ...

ProArtWork Pfizer's (NYSE:PFE) cash flow from operations in 2022, driven by sales of the company's COVID-19 vaccine and Paxlovid, hit $29.267 billion. Fast-forward to 2023, and with COVID largely behind us, revenue from those products plummeted, pushing cash flow from operations down to $8.7 billion. With that in mind, it's not difficult to understand why the stock fell by roughly 23% over the last year. But there is more to Pfizer than coronavirus meds. The firm has a solid drug pipeline, and in an industr ...

Pfizer (PFE) closed the latest trading day at $27.93, indicating a -0.43% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.1%. At the same time, the Dow lost 0.08%, and the tech-heavy Nasdaq gained 0.28%.Prior to today's trading, shares of the drugmaker had lost 1.85% over the past month. This has lagged the Medical sector's loss of 0.44% and the S&P 500's gain of 4.08% in that time.Analysts and investors alike will be keeping a close eye on the perfo ...

Don't ignore this drugmaker simply because it's been unable to come up with a full replacement for Lipitor.Pfizer (PFE -0.20%) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company has regularly raised its annual payout in recent years. Now that the dividend is well established, this streak isn't apt to end in the foreseeable ...

Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.The past few years have been tough ones for investors holding shares of Pfizer (PFE 1.26%). The Big Pharma stock is down by more than half from the peak it set in late 2021.Pfizer's stock price was hammered, but that didn't prevent the company from meeting and raising its dividend commitment. Last December, the pharmaceutical company raised its payout for the 15th consecutive year.Shares of Pfizer offer an eye-popping 6 ...